Ivosidenib - Latest Advances

The allosteric IDH1 inhibitor ivosidenib overcomes chemoresistance in intrahepatic cholangiocarcinoma models expressing wild-type IDH1.

Journal: The Journal of clinical investigation

Published: March 17, 2026

Pharmacologic progress in higher-risk MDS: an uphill battle.

Journal: Expert opinion on pharmacotherapy

Published: March 10, 2026

Discovery of a Hydroxamic Acid-Based HDAC11 Isoform-Selective Inhibitor with Oral Anti-AML Potency.

Journal: Journal of medicinal chemistry

Published: March 06, 2026

Ivosidenib for cholangiocarcinoma and acute myeloid leukaemia.

Journal: Australian prescriber

Published: February 25, 2026

Circulating tumor DNA-based detection of molecular residual disease in isocitrate dehydrogenase-mutant cholangiocarcinoma for biomarker-guided therapy.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 23, 2026

Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions.

Journal: Journal of personalized medicine

Published: February 16, 2026

IDH-mutant inhibitors enhance the sensitivity of IDH1-mutant gliomas to cysteine-methionine deprivation and ferroptosis.

Journal: bioRxiv : the preprint server for biology

Published: February 12, 2026

Quantitative benefit-risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies.

Journal: The Journal of antimicrobial chemotherapy

Published: January 19, 2026

Management of Acute Myeloid Leukemia: A Review.

Journal: Cancers

Published: January 13, 2026

Differentiation Syndrome in Acute Myeloid Leukemia: Molecular Mechanisms, Clinical Spectrum, and Emerging Therapeutic Paradigms.

Journal: International journal of molecular sciences

Published: December 29, 2025

Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.

Journal: Advances in therapy

Published: December 17, 2025